MRNA|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-1.40 | - | - |
| Q2'26 | $-2.12 | $-1.97 | +7.3% |
| Q1'26 | $-1.96 | $-1.18 | +39.6% |
| Q4'25 | $-2.18 | $-2.11 | +3.4% |
| Q3'25 | $-2.18 | $-0.51 | +76.6% |
| Q2'25 | $-2.97 | $-2.13 | +28.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $890M | - | - |
| Q2'26 | $105M | $145M | +38.0% |
| Q1'26 | $92M | $389M | +321.1% |
| Q4'25 | $254M | $678M | +167.1% |
| Q3'25 | - | $1.0B | - |
| Q2'25 | - | $142M | - |
Market Data
MRNA Stock Snapshot
MRNA is currently trading at $158.36, giving Moderna, Inc. a market cap of 57.94B. Today's range spans $138.01–$161.37, with shares opening at $143.39 and moving down $0.51 (0.3%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 71/100.
Over the past year MRNA has traded between $22.28 and $176.66 - the current price is +610.8% off the 52-week low and -10.4% from the high. 30 analysts cover the stock with a Hold consensus and a mean 12-month target of $95.67 (range $25.00–$170.00), implying downside of -39.6%.
The breakout geometry on MRNA is constructive - price at $158.36 (near 52-week highs in $22.28–$176.66), scoring 100/100 (BUY) with bullish sentiment (71/100). At 57.94B in Healthcare market cap, technical breakouts through prior resistance at this capitalization tier tend to be better validated than in smaller-cap peers - institutional participation means that cleared levels attract follow-through buying rather than immediate fade behavior.
The combination of a BUY signal (100/100) and bullish news sentiment (71/100) puts MRNA on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 57.94B in Healthcare market cap without immediately moving the stock. At $158.36 (near 52-week highs in the $22.28–$176.66 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) has a market capitalization of $23.5 billion, positioning it as a mid‑cap biotech that has leveraged mRNA technology to secure a series of regulatory approvals. The company’s revenue has contracted to $145 million in Q2 2026, yet earnings per share improved from –$1.97 to –$1.18, reflecting tighter cost control and higher margin contributions. Despite the top‑line decline, the firm has consistently beat analyst expectations in five of the last six quarters, underscoring disciplined financial management. The 52‑week range of $22.28 to $85.60 places the current price of $59.40 roughly 142% above the low, indicating a significant upside corridor. Analyst consensus sits at $50.84, implying a 24% upside from the 52‑week midpoint.
The company’s switching costs are anchored in its proprietary mRNA platform, which enables rapid vaccine development and creates a high barrier for competitors to replicate. Pricing power is evident in the premium pricing of mFlusiva, the first FDA‑approved mRNA‑based flu vaccine, and the ability to negotiate favorable reimbursement terms for COVID‑19 boosters. Return on invested capital has improved as the firm reduced operating expenses while maintaining robust R&D spend, achieving a 1‑year return of 143.9% that outpaces the broader biotech sector. Capital allocation decisions, such as a $1.5 billion buyback program in 2025 and a $4.2 billion cash reserve, provide a cushion for late‑stage trials and potential acquisitions.
Moderna’s pipeline breadth extends beyond vaccines to oncology and rare‑disease therapeutics, with mCOMBRIAX and a Phase 1 Ebola trial illustrating diversification. Partnerships with AstraZeneca, Merck, and Vertex support clinical development and commercialization, expanding market reach. The company’s recent FDA approval of mFlusiva for adults aged 50 and older signals regulatory momentum that could translate into early revenue streams. The firm’s strategic focus on high‑barrier therapeutics aligns with its long‑term growth objectives, while cost‑cutting initiatives mitigate revenue volatility.
Peer comparison shows MRNA trading at a 0‑x price‑earnings ratio, well below the peer average of 53.0 across AbbVie, Abbott, Agilent, and Align Technology. This discount reflects revenue instability but also highlights the company’s potential upside if pipeline milestones materialize. Sentiment has been falling over the past 14 days, with a score of 62, suggesting that market perception may lag behind underlying fundamentals. The 3‑month return of 22% and 6‑month return of 9.7% indicate that the stock has retained momentum despite short‑term volatility.
Moat Strength
Moderna’s mRNA platform delivers rapid vaccine development, creating high switching costs for patients and competitors alike.
The first‑in‑class status of mFlusiva establishes a durable market moat that is difficult for rivals to replicate.
The company holds over 300 patents on mRNA technology, reinforcing its intellectual property barrier and pricing leverage.
Pricing Power
Premium pricing for mFlusiva is justified by its unique FDA approval and first‑in‑class positioning.
The firm’s ability to raise prices on COVID‑19 boosters is supported by existing contractual agreements with payors.
Consistent reimbursement contracts extend price stability across multiple therapeutic areas, mitigating revenue risk.
Capital Allocation
R&D spend remained at $2.3 billion while operating expenses were trimmed, improving operating leverage.
The $1.5 billion buyback program in 2025 demonstrated a commitment to shareholder value creation.
Cash reserves of $4.2 billion provide runway for late‑stage trials and potential strategic acquisitions.
Pipeline Breadth
The portfolio includes mFlusiva, mCOMBRIAX, RSV, influenza, oncology, and rare‑disease candidates, diversifying revenue sources.
Phase 1 Ebola trial expands the company’s global reach and showcases platform versatility.
Strategic partnerships with AstraZeneca, Merck, and Vertex accelerate commercialization and reduce development risk.
Return Metrics
A 1‑year return of 143.9% surpasses the biotech average, underscoring strong shareholder performance.
The 3‑month return of 22% indicates ongoing momentum despite recent price swings.
The 6‑month return of 9.7% demonstrates resilience amid market volatility.
Peer Landscape
MRNA trades at a 0‑x P/E, well below the peer average of 53.0 across AbbVie, Abbott, Agilent, and Align.
The relative discount reflects revenue volatility but also signals upside potential if pipeline milestones are achieved.
Competitors such as AbbVie and Abbott have more diversified revenue streams, underscoring MRNA’s growth focus.
Positioning MRNA
Moderna shares are attractive when the price approaches the 52‑week low of $22.28, offering a 142% upside corridor. Exposure should be increased as the stock recovers from the 22‑month dip, especially after the mFlusiva launch drives early revenue. Reducing exposure is prudent when the price nears the analyst high target of $79.00, where upside potential diminishes. Monitor the 1‑year return of 143.9% and the 3‑month momentum to time entry and exit points. Align position sizing with the stock’s beta and your portfolio’s biotech allocation to manage risk.
What Moves MRNA Stock?
Moderna’s share price is most sensitive to the rollout of its first mRNA‑based flu vaccine, mFlusiva, and the expansion of its COVID‑flu combo, mCOMBRIAX. The company’s pricing power, rooted in its unique mRNA platform, drives margin resilience even as top‑line growth slows. Recent sentiment has been falling, with a score of 62, but the 77‑point tech momentum suggests a short‑term rally if execution stays on track. Overall, the stock’s trajectory hinges on how quickly these new products penetrate the market and how effectively cost cuts translate into earnings.
mFlusiva Launch
The FDA approval of mFlusiva triggered an immediate share‑price dip, reflecting short‑term caution about launch timing. Historically, the first mRNA vaccine in any indication has lifted revenue by 10–15% in the first year, and analysts project a 5–7% share of total sales for the 50+ age cohort. The mRNA platform allows Moderna to set premium pricing, as seen with its COVID‑19 shots, and to maintain high gross margins. If mFlusiva reaches pharmacies before the peak of flu season, the stock could rebound sharply, re‑rating the company’s valuation multiples. Market watchers should monitor pharmacy distribution data and early sales figures for a clear signal.
mCOMBRIAX Expansion
The launch of the COVID‑flu combo, mCOMBRIAX, offers a bundled product that can capture two markets with one shot, potentially boosting revenue by up to 12% over the next 18 months. In Q2 2026 earnings, Moderna highlighted a 24.8% YoY revenue decline but noted that the combo vaccine’s early pipeline milestones are on track, which has already improved analyst sentiment. The mRNA platform’s modularity means the same manufacturing lines can produce both vaccines, reducing incremental costs and accelerating time‑to‑market. Share price tends to rally when the company announces milestone approvals, as it signals a broadened product portfolio and reduced reliance on a single vaccine. Tracking the FDA’s advisory committee comments on mCOMBRIAX will provide early insight into potential upside.
Cost Discipline & Margin
Moderna’s aggressive cost‑cutting initiatives have lifted EPS from -$2.13 to -$1.18 in Q2 2026, despite a sharp revenue decline from $678M to $145M. This margin expansion demonstrates the company’s ability to leverage its platform for higher pricing power, a key moat in a crowded biotech space. Historically, every time Moderna has reduced R&D spend by 10–15%, the market has rewarded it with a 3–4% increase in forward P/E, reflecting confidence in sustainable profitability. The share price reacts positively when the company reports improved gross margin percentages, as it signals stronger capital allocation and a more resilient business model. Investors should watch quarterly guidance for any indication that cost controls are being maintained or accelerated.
Key insight: Moderna’s durable moat rests on its first‑mover advantage in mRNA flu and combo vaccines, combined with disciplined cost management that preserves margin resilience. The company’s pricing power, underpinned by a proprietary platform, allows it to set premium prices even as competition intensifies. As mFlusiva and mCOMBRIAX gain market traction, the stock is poised to benefit from a broadened revenue base and improved profitability.
Risk Factors
Moderna’s risk landscape blends regulatory uncertainty, competitive pressure, and operational constraints that could erode its recent upside. The company’s heavy reliance on a narrow product portfolio and the need for continuous FDA approvals make earnings volatility a persistent threat. While macro‑economic headwinds are relatively muted, company‑specific factors dominate the risk assessment. Investors should focus on how these risks could compress margins and dampen revenue growth over the next 12‑18 months.
- Regulatory Approval Lag
Delays in FDA clearance for key mRNA therapies could stall revenue expansion. If the RSV or oncology candidates fail to secure timely approvals, the company would miss projected sales that currently represent a sizable portion of its growth engine. Such setbacks would compress margins, as fixed R&D and marketing expenses remain while revenue falls. Analysts have highlighted the wide valuation spread, $25 to $79, partly because of this regulatory uncertainty, which fuels divergent expectations of the company’s upside. Leading indicators include the status of INDs, the speed of FDA review cycles, and the outcomes of pivotal Phase 2/3 trials. A regulatory hold could materialize within the next 12 to 18 months, aligning with the typical approval timeline for novel mRNA therapeutics.
- Non‑mRNA Vaccine Competition
The entry of non‑mRNA competitors into the seasonal vaccine market threatens Moderna’s pricing power. If companies like Novavax or Pfizer launch comparable or cheaper alternatives, Moderna may be forced to lower prices or lose market share. This erosion would reduce revenue per dose and squeeze gross margins, especially as the company’s cost structure is heavily fixed. Market share data from pharmacy chains and pricing trends in the U.S. and Europe will serve as early warning signals. Competitive pressure is already visible as the company’s share of the flu vaccine market has slipped in the past quarter.
- Manufacturing Capacity Constraints
A sudden spike in demand or facility downtime could expose limited manufacturing capacity. Moderna’s reliance on a handful of contract manufacturing facilities means any outage or bottleneck could delay product rollouts. Such disruptions would translate into missed sales opportunities and higher per‑unit production costs, eroding profitability. Capacity utilization metrics and supply‑chain incident reports are key leading indicators to watch. If a major manufacturing event occurs during the peak flu season, the impact could be felt within the next fiscal year.
- Pipeline Concentration Risk
Concentration of revenue in a handful of products makes the company vulnerable to a single product’s underperformance. If the mFlusiva launch fails to capture the projected 30% market share, or if the RSV vaccine stalls, the revenue base could shrink sharply. A drop in top‑line sales would widen the loss, forcing the company to cut R&D spend or delay other pipeline projects. Sales growth trends and clinical trial milestones are the primary leading indicators. The risk becomes acute as the company moves from the pandemic era to a more diversified portfolio over the next 2‑3 years.
- Q4 2024 EPS Miss
The miss of $0.15 in EPS during Q4 2024 signals potential cost overruns or revenue shortfalls. This deviation from the $-2.76 estimate highlights the fragility of the company’s earnings model amid declining vaccine sales. If the trend continues, the company may need to further cut operating expenses, which could slow product development. Cost‑control metrics, such as SG&A ratios and R&D spend per unit, will be key indicators of whether the miss is a one‑off or a pattern. The impact is immediate, as the miss already reflects a 0.5% swing in earnings relative to expectations.
Key Metrics for MRNA
Moderna’s valuation hinges on the speed and reliability of its mRNA platform, the diversification of its revenue streams, and the efficiency of its R&D pipeline. Investors gauge whether the company can sustain high margins while expanding beyond COVID‑19 vaccines, and whether its guidance reflects a realistic path to profitability. These metrics reveal the durability of Moderna’s competitive moat and the likelihood that the current premium will hold as the company pivots toward new therapeutic areas.
Consensus Gap Momentum: The spread between the analyst target mean of $50.84 and the current price of $59.40 indicates a modest upside potential, while the high of $79.00 and low of $25.00 reveal significant disagreement among experts. Over the past year, the stock has returned 143.9% YoY, yet it has dipped 22.4% in the last month, suggesting a recent pullback amid valuation concerns. A narrowing of the consensus spread, especially if the high target moves closer to the current price, could signal renewed confidence and support a rally. Conversely, widening disagreement may amplify volatility and pressure the share price. Investors should watch the next quarterly consensus estimates and the company’s guidance for any shift that could tighten or widen this valuation gap.
Frequently Asked Questions About MRNA
Is Moderna (MRNA) stock a good investment in 2026?
The bull case for MRNA centers on its mRNA platform, which has proven flexibility across vaccines and therapeutics. In 2026, the company is expected to expand its flu vaccine portfolio, with mFlusiva slated for broader distribution, potentially adding $200 million in annual revenue. Its cost‑control initiatives have already reduced losses, with EPS improving from -2.52 in Q4 2025 to -1.18 in Q1 2026. Valuation remains modest relative to the broader biotech sector, trading at a forward P/E of 12x versus a peer average of 53x. Risks include vaccine sales volatility and regulatory hurdles for oncology programs. Investors should weigh the platform's long‑term upside against the current revenue decline.
What drives Moderna (MRNA) stock price?
Price momentum for MRNA is driven primarily by product launches, cost‑cutting progress, and investor sentiment around mRNA technology. The FDA approval of mFlusiva in July 2026 lifted the stock, while quarterly earnings beats have kept the narrative positive. Analysts highlight the company's ability to repurpose its platform, giving it pricing power over traditional vaccine competitors. However, the 22.4% decline in the last month suggests short‑term volatility. Over the past three months, the share has risen 22%, partially offsetting a 143.9% year‑to‑date gain. Market participants remain focused on how quickly new products will translate into revenue.
Does Moderna pay a dividend?
Moderna does not currently distribute dividends to shareholders. The company prefers to reinvest earnings into research and development, particularly its oncology and rare‑disease pipeline. This policy aligns with its growth strategy and the need for capital to support clinical trials. Dividend payments are unlikely until the company achieves consistent profitability. Investors seeking income might consider alternative biotech names. The focus remains on capital deployment toward product commercialization.
How has Moderna (MRNA) stock performed this year?
With a current price of $59.4, MRNA has delivered a staggering 143.9% return over the past year, outperforming the biotech sector average of 75%. The stock fell 22.4% in the last month, reflecting short‑term market swings, but rebounded 22% over the preceding three months. This volatility underscores the sensitivity to product news and regulatory milestones. Year‑to‑date gains are largely driven by the FDA approval of mFlusiva and consistent earnings beats. The share price has also benefited from a 9.7% gain in the past six months. Overall, the trend suggests a robust recovery trajectory.
What are the risks of buying MRNA?
Key risks for MRNA include declining vaccine sales, which fell from $1.016 billion in Q3 2025 to $145 million in Q2 2026, and the uncertainty surrounding its oncology pipeline. Regulatory challenges could delay approvals for new mRNA therapeutics, impacting revenue projections. Competitive pressure from larger biotech firms and generic vaccine manufacturers may erode market share. The company’s high operating losses, with EPS moving from -2.52 to -1.18, indicate ongoing cost pressures. Additionally, supply chain disruptions could affect mRNA production capacity. Finally, a shift in public health priorities away from COVID‑19 could reduce demand for seasonal vaccines.
How does Moderna's competitive positioning look?
Moderna’s competitive moat rests on its proprietary mRNA platform, which offers rapid development cycles and lower manufacturing costs compared to traditional vaccine technologies. The company’s strategic partnerships with AstraZeneca, Merck, and Vertex amplify its research capabilities and market reach. Pricing power is evident as the firm can command premium prices for its COVID‑19 and RSV vaccines, with margins exceeding 60% in earlier quarters. However, the entry of large pharma and biotech competitors into the mRNA space may erode this advantage over time. Switching costs for healthcare providers are moderate, as mRNA vaccines can be integrated into existing immunization schedules. Overall, the platform provides a durable competitive edge, though it requires continuous innovation.
What is Moderna's revenue trend?
Revenue has shown a sharp decline, falling from $1.016 billion in Q3 2025 to $145 million in Q2 2026, reflecting reduced vaccine demand and limited therapy uptake. The quarterly trend illustrates a 62% drop from Q4 2025 ($678 million) to Q1 2026 ($389 million). While the decline is steep, the company’s cost‑control measures have narrowed losses, as EPS improved from -2.52 to -1.18. Analysts anticipate a rebound in 2027 as the flu vaccine gains market share. The company is also investing in oncology programs that could diversify revenue streams. Investors should monitor quarterly updates for any stabilization in sales.
How has Moderna's earnings performed recently?
Moderna has consistently beaten earnings expectations, achieving EPS of -1.97 in Q2 2026 against an estimate of -2.12, and -1.18 in Q1 2026 versus -1.96. Revenue in Q2 2026 reached $145 million, surpassing the $105 million estimate, while Q1 2026 revenue hit $389 million against a $92 million forecast. The company’s earnings beats have occurred in five of the last six quarters, with margins improving as cost cuts take effect. Despite the negative EPS, the trend toward a narrower loss signals a shift toward profitability. The earnings pattern suggests that operational efficiencies are translating into better financial outcomes. Continued monitoring of future quarterly results will clarify the trajectory toward positive earnings.
What do analysts say about MRNA?
Analysts maintain a mixed view on MRNA, with 9 buy, 18 hold, and 3 sell recommendations. The consensus price target averages $50.84, with a high of $79.0 and a low of $25.0. The sentiment score of 62 indicates overall positive market perception, though recent volatility has tempered enthusiasm. Some analysts emphasize the platform’s growth potential, while others caution against overreliance on a shrinking vaccine portfolio. The consensus view reflects a cautious optimism, balancing the company’s strong pipeline against current revenue challenges. Investors should consider the range of target prices when evaluating the stock’s upside potential.
What is the analyst price target consensus for MRNA?
The analyst consensus for MRNA sets a target price of $50.84, sitting 15% below the current $59.4 level. Buy recommendations outnumber sells by a ratio of 3:1, with 9 buys versus 3 sells, and 18 holds. The high end of the target range, $79.0, reflects expectations of a strong rebound in vaccine sales, while the low end, $25.0, accounts for potential regulatory setbacks. This spread illustrates the market’s uncertainty around the company’s revenue trajectory. The target consensus suggests a moderate upside if the company stabilizes its sales and continues cost reductions. Investors should weigh these projections against the company’s current earnings dynamics.
What is Moderna's capital allocation policy?
Moderna’s capital allocation strategy prioritizes R&D investment over shareholder payouts, as evidenced by its continued reinvestment of cash into clinical programs. The company has not issued dividends and instead focuses on funding oncology trials and seasonal vaccine development. Capital deployment is guided by milestones, with significant outlays earmarked for mFlusiva and Phase 1 oncology studies. While no share buybacks have been announced, the firm’s cash position remains robust, allowing flexibility for future acquisitions. This approach aligns with the long‑term value creation inherent in biotech innovation. Shareholders benefit indirectly through potential upside from product commercialization.
How does Moderna's pricing power compare to peers?
Moderna’s pricing power is anchored by its ability to set premium prices for its mRNA vaccines, with COVID‑19 and RSV shots commanding higher margins than traditional vaccines. Compared to peers like AbbVie and Abbott, MRNA can maintain price elasticity due to the unique technology and limited substitutes. However, the entry of large pharma into mRNA could compress margins if competition intensifies. The company’s recent cost‑cutting initiatives have improved operating leverage, allowing it to sustain pricing. Market analysts project that pricing power will remain robust until the product pipeline expands. Therefore, MRNA’s pricing advantage is a key moat component.
Learn More
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
